×
S&P 500   3,946.52 (+0.13%)
DOW   31,973.83 (+0.14%)
QQQ   285.65 (-0.55%)
AAPL   138.21 (-1.53%)
MSFT   258.31 (-0.50%)
FB   180.56 (-0.40%)
GOOGL   2,100.65 (-0.88%)
AMZN   2,108.60 (+1.28%)
TSLA   623.00 (-0.82%)
NVDA   159.96 (-0.98%)
BABA   83.63 (+1.41%)
NIO   14.89 (+1.78%)
AMD   90.26 (-0.99%)
MU   67.42 (+1.20%)
T   21.13 (-0.14%)
GE   74.54 (+0.03%)
F   12.53 (+0.89%)
DIS   102.21 (+0.61%)
AMC   10.70 (+2.98%)
PFE   53.75 (+0.64%)
PYPL   78.05 (-0.76%)
NFLX   179.84 (-0.28%)
S&P 500   3,946.52 (+0.13%)
DOW   31,973.83 (+0.14%)
QQQ   285.65 (-0.55%)
AAPL   138.21 (-1.53%)
MSFT   258.31 (-0.50%)
FB   180.56 (-0.40%)
GOOGL   2,100.65 (-0.88%)
AMZN   2,108.60 (+1.28%)
TSLA   623.00 (-0.82%)
NVDA   159.96 (-0.98%)
BABA   83.63 (+1.41%)
NIO   14.89 (+1.78%)
AMD   90.26 (-0.99%)
MU   67.42 (+1.20%)
T   21.13 (-0.14%)
GE   74.54 (+0.03%)
F   12.53 (+0.89%)
DIS   102.21 (+0.61%)
AMC   10.70 (+2.98%)
PFE   53.75 (+0.64%)
PYPL   78.05 (-0.76%)
NFLX   179.84 (-0.28%)
S&P 500   3,946.52 (+0.13%)
DOW   31,973.83 (+0.14%)
QQQ   285.65 (-0.55%)
AAPL   138.21 (-1.53%)
MSFT   258.31 (-0.50%)
FB   180.56 (-0.40%)
GOOGL   2,100.65 (-0.88%)
AMZN   2,108.60 (+1.28%)
TSLA   623.00 (-0.82%)
NVDA   159.96 (-0.98%)
BABA   83.63 (+1.41%)
NIO   14.89 (+1.78%)
AMD   90.26 (-0.99%)
MU   67.42 (+1.20%)
T   21.13 (-0.14%)
GE   74.54 (+0.03%)
F   12.53 (+0.89%)
DIS   102.21 (+0.61%)
AMC   10.70 (+2.98%)
PFE   53.75 (+0.64%)
PYPL   78.05 (-0.76%)
NFLX   179.84 (-0.28%)
S&P 500   3,946.52 (+0.13%)
DOW   31,973.83 (+0.14%)
QQQ   285.65 (-0.55%)
AAPL   138.21 (-1.53%)
MSFT   258.31 (-0.50%)
FB   180.56 (-0.40%)
GOOGL   2,100.65 (-0.88%)
AMZN   2,108.60 (+1.28%)
TSLA   623.00 (-0.82%)
NVDA   159.96 (-0.98%)
BABA   83.63 (+1.41%)
NIO   14.89 (+1.78%)
AMD   90.26 (-0.99%)
MU   67.42 (+1.20%)
T   21.13 (-0.14%)
GE   74.54 (+0.03%)
F   12.53 (+0.89%)
DIS   102.21 (+0.61%)
AMC   10.70 (+2.98%)
PFE   53.75 (+0.64%)
PYPL   78.05 (-0.76%)
NFLX   179.84 (-0.28%)
NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Forecast, Price & News

$1.50
-0.07 (-4.46%)
(As of 05/25/2022 09:38 AM ET)
Add
Compare
Today's Range
$1.49
$1.50
50-Day Range
$1.47
$2.03
52-Week Range
$1.19
$3.27
Volume
1,959 shs
Average Volume
1.24 million shs
Market Capitalization
$338.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.82
30 days | 90 days | 365 days | Advanced Chart
Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Outlook Therapeutics logo

About Outlook Therapeutics

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Headlines

Outlook Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
9
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.15 million
Book Value
$0.16 per share

Profitability

Net Income
$-53.16 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
220,746,000
Market Cap
$338.91 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/13/2022
Today
5/25/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

484th out of 1,420 stocks

Biological Products, Except Diagnostic Industry

78th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

Is Outlook Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Outlook Therapeutics stock.
View analyst ratings for Outlook Therapeutics
or view top-rated stocks.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Outlook Therapeutics
.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its earnings results on Friday, May, 13th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.03.
View Outlook Therapeutics' earnings history
.

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics's stock reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for OTLK?

1 brokerages have issued 1-year price targets for Outlook Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Outlook Therapeutics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts' price targets for Outlook Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Outlook Therapeutics' key executives?
Outlook Therapeutics' management team includes the following people:
  • Mr. Ralph H. Thurman, Independent Exec. Chairman (Age 73)
  • Mr. C. Russell Trenary III, Pres, CEO & Director (Age 64, Pay $622.66k) (LinkedIn Profile)
  • Mr. Lawrence A. Kenyon CPA, Exec. VP, CFO, Treasurer, Company Sec. & Director (Age 56, Pay $661.18k)
  • Mr. Terry Dagnon, Chief Operations Officer (Age 60, Pay $300k) (LinkedIn Profile)
  • Mr. Jeffrey Evanson, Chief Commercial Officer (Age 53, Pay $300k) (LinkedIn Profile)
  • Rick Gregory, Director of Marketing & Communications
  • Ms. Alicia Tozier, Sr. VP, Marketing & Market Access
  • Mr. Joel Prieve, Sr. VP of Commercial Operations
  • Dr. Balu N. Balasubramanian, Advisor
  • Ms. Elizabeth A. Yamashita, Advisor (Age 61)
What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and CNBX Pharmaceuticals (CNBX).

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.98%), Vanguard Group Inc. (2.51%), State Street Corp (0.74%), Vista Finance LLC (0.44%), Northern Trust Corp (0.44%) and Renaissance Technologies LLC (0.33%). Company insiders that own Outlook Therapeutics stock include C Russell Trenary III, Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Randy H Thurman, Syntone Ventures Llc, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends for Outlook Therapeutics
.

Which major investors are selling Outlook Therapeutics stock?

OTLK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Envestnet Asset Management Inc., and Advisor Group Holdings Inc..
View insider buying and selling activity for Outlook Therapeutics
or view top insider-selling stocks.

Which major investors are buying Outlook Therapeutics stock?

OTLK stock was bought by a variety of institutional investors in the last quarter, including Vista Finance LLC, BlackRock Inc., Northern Trust Corp, State Street Corp, Charles Schwab Investment Management Inc., Jane Street Group LLC, First Merchants Corp, and Graypoint LLC. Company insiders that have bought Outlook Therapeutics stock in the last two years include C Russell Trenary III, Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Randy H Thurman, Syntone Ventures Llc, Terry Dagnon, and Yezan Munther Haddadin.
View insider buying and selling activity for Outlook Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $1.50.

How much money does Outlook Therapeutics make?

Outlook Therapeutics has a market capitalization of $338.91 million and generates $8.15 million in revenue each year. The company earns $-53.16 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does Outlook Therapeutics have?

Outlook Therapeutics employs 9 workers across the globe.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is www.outlooktherapeutics.com.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company can be reached via phone at (609) 619-3990 or via email at [email protected].

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.